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ABSTRACT
Introduction Sarcoidosis is a multisystem disease, 
predominantly affecting the lungs but can involve the 
heart, resulting in cardiac sarcoidosis (CS). Patients 
require MRI/Positron Emission Tomography (PET) scans for 
diagnosis. Echocardiography, ECG and Holter monitoring 
may be indicative but not diagnostic alone. Patients 
can present late with conduction defects, heart failure 
or sudden death. The CASPA (CArdiac Sarcoidosis in 
PApworth) study protocol aims to (1) use MRI to identify 
CS prevalence; (2) use speckle- tracking echocardiography, 
signal averaged ECG and Holter monitoring to look for 
diagnostic pathways; and (3) identify serum proteins which 
may be associated with CS.
Methods and analysis Participants with pulmonary 
sarcoidosis (and no known cardiac disease) from Royal 
Papworth Hospital will have the following: cardiac MRI 
with late gadolinium, two- dimensional transthoracic 
echocardiography with speckle tracking, signal 
averaged ECG and 24- hour Holter monitor. They will 
provide a serum sample for brain natriuretic peptide 
levels and proteomics by liquid chromatography 
coupled to high- resolution mass spectrometry. All data 
will be collected on OpenClinica platform and analysed 
approximately 6 months after final patient recruitment.
Ethics and dissemination The Camden & Kings Cross 
Research Ethics Committee approved the protocol 
(REC number: 17/LO/0667). Integrated Research 
Approval System (IRAS) 222 720. Dissemination of 
findings will be via conference presentations and 
submitted to peer- reviewed journals.
INTRODUCTION
This is a protocol paper for the CASPA(-
CArdiac Sarcoidosis in PApworth) study. 
Sarcoidosis is a multisystem disease charac-
terised by non- caseating granulomas which 
predominantly affect the lungs in more than 
90% of cases. Extrapulmonary sites include 
the heart, skin, liver, eyes and central nervous 
system.1 The aetiology is not fully understood 
but is likely due to an interplay between an 
environmental trigger and a dysregulation of 
the host immune system.2 3 Previous clinical 
studies estimate that cardiac sarcoidosis (CS) 
occurs in approximately 5% of cases1 but 
autopsy studies reported cardiac involvement 
in about one- fourth of cases in the USA or 
Europe4 and higher in Japan, suggesting up 
to 69% involvement.5 The incidence of CS is 
higher in Japanese patients with sarcoidosis, 
and it is the leading cause of sarcoid- 
attributed death (77%–85% in Japan).6 The 
true incidence is therefore hypothesised 
to be in between these figures, but this is 
complicated as the clinical diagnosis of CS 
can be challenging. The disease can be diffi-
cult to both diagnose and manage; never-
theless, a significant proportion of patients 
with limited pulmonary involvement have a 
mild course with good outcome, often not 
requiring corticosteroids or immunosuppres-
sion treatment.7 However, a large retrospec-
tive study of over 600 000 US hospital admis-
sions for patients with sarcoidosis showed that 
a 31% had coexisting cardiac disease.8 The 
heart can be involved in sarcoidosis in one 
of three ways. First, patients with sarcoidosis 
are at higher risk of cardiovascular disease 
including heart failure and ischaemic heart 
disease.9 Second, they can develop pulmo-
nary hypertension with associated right heart 
dysfunction. Third, they can have ‘true’ CS 
where granulomas directly affect the heart 
leading to conduction disturbance, atrial or 
ventricular tachyarrhythmia, heart failure or 
sudden death. CS is reported to be the second 
most common cause of sarcoid- related 
mortality and can affect young and other-
wise relatively healthy patients.10 An early and 
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accurate diagnosis is therefore paramount to prevent 
cardiac- related morbidity and mortality.
The 2014 joint consensus statement from the World 
Association for Sarcoidosis and Other Granulomatous 
disorders (WASOG), the American College of Cardiology 
and the American College of Chest Physicians states that 
there are no currently accepted international guide-
lines for the diagnosis of CS.11 A cardiac biopsy to reveal 
non- caseating granulomas is the gold standard single 
diagnostic method but is rarely performed due to the 
invasive nature of the test, associated morbidity and low 
diagnostic sensitivity resulting from patchy cardiac infil-
tration by granulomas.12 Abnormalities on non- invasive 
cardiac imaging modalities (MRI or Positron Emission 
Tomography (PET) scan), coupled with the presence 
of extracardiac sarcoidosis, are taken by most experts as 
representing a confident diagnosis of CS.11 Other modal-
ities such as ECG and Holter ECG monitoring may be 
indicative of a diagnosis but cannot be diagnostic of CS 
by themselves due to low sensitivity and specificity.
The lack of consensus means that studies are urgently 
needed to accurately quantify the prevalence and severity 
of disease. In the current study, we propose a three- 
pronged investigation to improve our understanding and 
to optimise the diagnostic pathway of CS in patients with 
pulmonary sarcoidosis and no prior significant cardiac 
disease.
First, to use state- of- the- art MRI scanning (including 
water- sensitive sequences and T2 to assess for oedema 
and infiltration) to quantify prevalence of CS in a popula-
tion of patients with newly diagnosed pulmonary sarcoid-
osis. This will allow us to accurately identify prevalence of 
cardiac involvement in our population.
Second, to identify the predictive value of 12- lead 
ECG, signal- averaged ECG, 24- hour ambulatory Holter 
monitoring, two- dimensional (2D) transthoracic echo-
cardiography combined with speckle- tracking analysis, 
in identifying evidence of underlying cardiac involve-
ment (using MRI as the gold standard) and formulate 
the optimal diagnostic pathway that will allow patients to 
be screened for cardiac involvement without the need 
for the ‘gold standard’ MRI which requires expertise to 
perform and interpret.13
Third, to perform cutting- edge proteomics and cyto-
kine profiling on sera from our population to iden-
tify biomarkers associated with cardiac involvement. 
The identification of specific proteins may allow us to 
create simple and cost- effective blood tests to help accu-
rately diagnose CS prior to confirmation with imaging 
modalities.13
METHODS AND ANALYSIS
Study design and patient selection
This is a prospective observational cohort study (planned 
to run from 2017 to 2021) for patients with pulmonary 
sarcoidosis with confirmed diagnosis by the Interstitial 
Lung Disease (ILD) MDT at Royal Papworth Hospital 
NHS Foundation Trust, which receives referrals from the 
surrounding area (East of England). Additional partici-
pant identification centres (PICs) are open at Cambridge 
University Hospitals and Norfolk and Norwich NHS Trust. 
All consecutive new patients with sarcoidosis discussed at 
MDT or seen in clinic who meet the eligibility criteria 
(figure 1) will be approached and invited to take part in 
the study.
The study will assess for any cardiac disease (including 
and specifically CS) in participants with pulmonary 
sarcoidosis (and no significant cardiac disease). Study 
investigations will be conducted in one visit (figure 2). No 
therapeutic intervention will be carried out in the study. 
Any participant with confirmed CS diagnosis (based 
on MRI findings) will be offered further investigations 
(including electrophysiology studies where indicated) 
and treatment as deemed necessary by a consultant 
cardiologist and consultant electrophysiologist with a 
specialist interest in the management of CS. This group 
will then be offered ongoing clinical follow- up within the 
ILD service.
Study objectives
The primary objective is to assess the prevalence of CS in 
patients with a new diagnosis of pulmonary sarcoidosis 
using cardiac MRI as the gold standard investigation 
for the detection of cardiac sarcoidosis. The secondary 
objectives are (1) to determine the optimal diagnostic 
pathway of investigation to identify confirmed cardiac 
involvement on cardiac MRI using 12- lead ECG, signal- 
averaged ECG, 24- hour ambulatory Holter monitoring, 
and 2D transthoracic and speckle- tracking echocardiog-
raphy; and (2) to determine the ability of novel serum 
biomarkers to identify confirmed cardiac involvement on 
cardiac MRI.
Figure 1 Inclusion and exclusion criteria for the CASPA 
(CArdiac Sarcoidosis in PApworth) study. EF, Ejection 
Fraction.




Cardiac MRI scans will be performed with a 1.5 T Siemens 
Avanto or Aera MRI scanner (Siemens Healthcare, 
Erlangen, Germany) using a dedicated eight- channel 
phased- array cardiac coil under ECG gating and breath- 
holding in line with standard recommendations. To 
evaluate the anatomy of the left and right ventricles cine 
images with steady- state free precession will be obtained 
from short axis and long axis (slice thickness 8 mm, inter-
slice gap 0 mm). Black blood T2- weighted images will 
be acquired to assess for oedema and infiltration in the 
short- axis orientation before administration of contrast 
media. Late gadolinium imaging will assess presence 
and anatomical distribution of late myocardial scar. Ten 
minutes after the administration of a gadolinium- based 
contrast medium (0.2 mmol/kg, Gadobutrol, Bayer AG, 
Leverkusen, Germany), contiguous short- axis slices from 
the base to the apex of the left ventricle will be acquired 
using a breath- holding ECG- gated sequence as well as 
standard long axis sequences. Single shot phase sensitive 
inversion- recovery LGE images will also be acquired.
Cardiac MRI (CMR) images will be randomised by 
expert radiologists. Left and right ventricular volume 
and ejection fraction will be measured offline using 
standardised postprocessing recommendations using 
commercially available software (CVI42; Circle Cardio-
vascular Imaging, Calgary, Alberta, Canada) and the 
presence of localised wall thinning and regional wall 
motion abnormalities determined. Extent and distribu-
tion of LGE will be determined by visual assessment with 
segmental analysis of anatomical distribution and pattern 
of late gadolinium enhancement as epicardial, intramyo-
cardial or subendocardial. An abnormal CMR will be 
defined as the presence of Left Ventricular (LV) or Right 
Ventricular (RV) regional wall motion abnormalities, 
localised hypertrophy or wall thinning of the RV or LV, 
LV systolic dysfunction (as defined by an Left Ventricular 
Ejection Fraciton (LVEF) <50%) or the presence of LGE 
in a non- vascular distribution.
2D transthoracic echocardiography
Standard 2D echocardiographic data will be obtained 
from the study performed on the same day as the CMR. 
All studies will be performed on a Philips IE33 or EPIC 
System (Philips Medical Systems, The Netherlands) with 
an S5 transducer. Chamber quantification and function, 
and the presence of valvular heart disease will be assessed 
according to the published American Society of Echocar-
diography guidelines.14 2D data sets for speckle- tracking 
analysis include three short- axis views (basal, midven-
tricular, apical) and three apical longitudinal views 
(4- chamber, 2- chamber and 3- chamber). Adjustments in 
sector depth and angle will be made to yield a temporal 
resolution of 80–100 frames per second. A minimum of 
40 frames per cycle is required for offline analysis (with a 
range of 40–82 frames per cycle achieved). The speckle- 
tracking programme, VVI V.3.0.0 (Siemens Healthcare, 
Mountain View, California, USA) will be applied to the 
echocardiographic images from archived studies, allowing 
endocardial, myocardial and epicardial strain param-
eter assessment. Longitudinal strain will be measured 
from the apical 4- chamber, apical 2- chamber and apical 
3- chamber views on echocardiography. Circumferential 
strain will be measured in three short- axis views (basal 
level at the mitral valve, midventricular level at the papil-
lary muscles and the apical level at the true LV apex). All 
echocardiographic images will be analysed in a random 
order by a single reader. An abnormal echocardiogram 
will be defined as the presence of LV or RV regional wall 
motion abnormalities, localised hypertrophy or thinning 
of the LV or RV myocardium, or LV systolic dysfunction 
as represented by an LVEF <50% (assessed by Biplane 
Simpsons method from 2D data).
12-lead ECG and ambulatory Holter monitoring
Standard resting 12- lead ECG will be performed on all 
study participants as per current clinical practice. They 
will undergo a 24- hour period of ambulatory ECG moni-
toring as per standard clinical practice and the monitor 
will be removed by the participant at home after the 
24- hour period and posted back (with a prepaid enve-
lope) to the study site.
Signal-averaged ECG (SAECG)
Resting SAECG will be performed concurrent with the 
12- lead ECG to record low- amplitude electrical activity 
in the myocardium by averaging a large number of 
Figure 2 CASPA (CArdiac Sarcoidosis in PApworth) study 
investigations. All patients will have the tests shown in a 
single study visit. A blood sample will additionally be taken 
for serum brain natriuretic peptide (BNP) analysis and 
subsequently stored as serum for proteomics. Any patients 
identified as having cardiac sarcoidosis (CS) on MRI will be 
offered a clinical review with an electrophysiologist with a 
view for an Electrophysiology (EP) study.
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high- resolution QRS complex recordings. The following 
criteria will be used to determine the presence of late 
potentials: (1) filtered QRS duration ≥114 ms, (2) 
RMS‐40<20 μV, and (3) LAS‐40>38 ms. Late potentials 
are generally considered present, when at least two of 
three conventional or modified criteria are satisfied.
Clinical data collection
Clinical observations for routine outpatient clinics 
and medical history will be recorded at the study visit, 
including respiratory (breathlessness and presence of 
cough) and cardiac symptoms (palpitations and dizzi-
ness). Additionally, we will document any steroid medi-
cations (oral or inhaled) and the latest results for rele-
vant routine clinical assessments including chest radio-
graphs, high- resolution CT, pulmonary function tests 
and 6- minute walk test.
Proteomic analysis
Serum proteins will be quantitated using label- free quan-
titative mass spectrometry. Each serum sample will be 
processed by liquid chromatography coupled to high- 
resolution mass spectrometry to generate an intensity 
value for approximately 600 serum proteins. These data 
will be stratified by cardiac involvement in sarcoidosis 
to determine potential serum biomarkers associated 
with CS (based on MRI diagnosis of CS) for hypothesis- 
generating research. Any novel biomarkers will also be 
correlated with serum B- type natriuretic peptide levels 
which are taken at time of patient study visit.
Sample size calculations and statistical analysis
A sample size calculation of 104 participants is based 
on the expected 30% prevalence of CS in our patient 
cohort, assuming 0.95 specificity and sensitivity of the 
cardiac MRI (as the proposed gold standard test for the 
purpose of this proposal) and 0.064 precision of the 
90% CI. With regard to our secondary objectives, we will 
use signal averaged ECG (SAECG), 24- hour ambulatory 
Holter monitoring and speckle- tracking echocardiogram 
as surrogate variables for MRI. All of them are binary 
variables (0=no heart problem, 1=heart problem). Binary 
logistic regression will associate MRI outcome (yes/no) 
with each of the three alternatives, independently, in 
conjunction with additional confounders such as age, sex 
and ethnicity. Hence, the three models will be identical, 
but for ECG, 24- hour tape or echo, only one will appear 
in each model. The area under receiver operating char-
acteristic curve will be calculated for the overall discrimi-
nation assessment of the model and model comparisons. 
In addition, pseudo R- squared15 will also be reported and 
alternatively used for model comparisons as well.
Study oversight and data analysis plan
A multidisciplinary steering committee has been formed 
which will include study investigators, research nurses, 
sponsor and funder representatives, study statistician and 
data manager, plus a patient and public representative. 
It will convene at 6 monthly intervals. All data including 
clinical records, informed consent forms and patient 
information sheets will be stored at Royal Papworth NHS 
Trust as per standard data protection guidelines. Data 
will be collected either at the time of visit or subsequently 
by clinical notes analysis and will be entered into a study- 
specific electronic case report form built on the enter-
prise edition of the clinical data management system, 
OpenClinica. All data will be analysed at the end of the 
data collection period (approximately 6 months after 
the final patient has been recruited). The local standard 
operating procedure (SOP) for archiving of research 
studies will be followed (Reference RPH:SOP011).
Patient and public involvement
The original research question and the need for 
improved testing for CS were discussed with patients with 
pulmonary sarcoidosis from both the Royal Papworth 
Hospital and patients who were members of the charity 
Sarcoidosis UK (at the time called SILA). After these 
initial discussions, patients had no further input into the 
study design. Individual participants will have access to 
their own study results and all participants will be given 
access to final publications.
Ethics and dissemination
The London – Camden & Kings Cross Research Ethics 
Committee has approved the study protocol (REC 
number: 17/LO/0667). Integrated Research Approval 
System (IRAS) 222 720. Dissemination of findings will be 
via presentations at clinical academic conferences and 
submitted to peer- reviewed scientific journals.
DISCUSSION
The prevalence of CS (especially in patients with no overt 
cardiac signs or symptoms) in the UK is unknown. World-
wide, there is variation between studies and countries. For 
this reason, the primary objective of this study is to iden-
tify the number of patients who have MRI evidence of CS 
within a group of 104 patients with pulmonary sarcoidosis. 
Clinical data have suggested that only 5% of all patients with 
sarcoidosis have clinically apparent CS1 but autopsy studies 
from the USA and Japan have suggested that this figure may 
be higher, between 16% and 69%.5 6 16–19 In one small study of 
patients with sarcoidosis who died suddenly, autopsy revealed 
granulomas present in the left ventricle in all 17 patients.20 
As such, CS may lead to conduction disturbances including 
and up to complete heart block, atrial or ventricular tachyar-
rhythmias, congestive heart failure or sudden death. Rarer 
findings which have been reported include valve defects and 
pericardial effusions.21 22 The consequences of this may be 
catastrophic for patients with mild pulmonary involvement, 
and as such, an accurate understanding of CS prevalence is 
important.
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The diagnosis of CS relies on imaging as features from the 
history and examination of a suspected patient are unreli-
able. A history of palpitations may be elicited but this could 
also be due to systemic activity in sarcoidosis or side effects 
of medications including corticosteroids.23 Patients may 
complain of breathlessness out of context with lung disease 
but again this may be difficult to quantify and distinguish 
from pulmonary sarcoidosis alone.24 25 On examination, 
patients may have signs of cardiac failure and a number of 
experts have suggested clinical review pathways which incor-
porate symptoms and signs into a diagnostic pathway10 but 
these are always taken together with appropriate imaging 
and cannot diagnose CS alone.
The current gold standard for diagnosis of CS (aside from a 
cardiac biopsy) is a compatible image suggesting CS on MRI or 
PET scan taken together with a secure extracardiac (most often 
pulmonary) diagnosis of sarcoidosis.11 MRI uses gadolinium as 
a contrast agent and delayed enhancement of this has a sensi-
tivity up to 100% for diagnosis of CS with a lower specificity 
of approximately 80%.26 Recent use of T2 mapping to detect 
changes in water distribution (relating to areas of oedema) 
may increase accuracy and allow for serial MRI measurements 
to monitor the extent of CS.27 Fluorodeoxyglucose- positron 
emission tomography (FDG- PET) scans have similar levels of 
accuracy for diagnosis of CS.28 However, both MRI and PET 
scans are expensive to perform and interpret (often with a 
level of subjective analysis) and depend on specific cardiac or 
radiological expertise. These scanners may not be available 
in all hospitals and even if they are, they may be prioritised 
for other diseases, for example, cardiac conditions (MRI) or 
cancers (PET). MRI requires the use of gadolinium contrast 
which has the potential to cause contract reaction in a minority 
of patients29 and PET scans have a radiation exposure. FDG- 
PET scanning also requires either a specific high- fat, low- 
carbohydrate diet, a period of fasting or a heparin infusion 
prior to scanning to increase the accuracy of the imaged meta-
bolic update in the areas of cardiac sarcoidosis.30 31 For these 
reasons, it is important to find alternative reliable tests which 
may be more accessible and interpreted.
Echocardiogram has previously been shown in some 
studies to be abnormal in up to 70% of patients with CS, the 
most common finding being left ventricular dysfunction.23 
Other findings may include septal or wall dyskinesia6 with 
valve disease related to sarcoidosis less common.32 However, 
another one more recent study showed that echocardiog-
raphy added to cardiac history and ECG did not change 
sensitivity of the initial screening strategy (68.8% vs 72.9%). 
Despite a high positive predictive value (83.9%), echocardi-
ography had a low sensitivity (27.1%).13 The additional use 
of speckle- tracking echocardiography to measure of global 
longitudinal strain (GLS) is thought to significantly increase 
the sensitivity of CS diagnosis using echocardiogram alone 
with a reduction of GLS having a sensitivity and specificity of 
>90% in one study.33 However, this requires additional anal-
ysis and interpretation and is not available in every hospital 
echocardiography department.
The use of a standard 12- lead ECG is part of the initial 
screening of all patients with sarcoidosis but is thought to be 
normal in up to 50% of all patients with CS.25 When they are 
abnormal, the most common findings are conduction distur-
bances and arrhythmias.34 The additional use of a signal aver-
aged ECG (which works to average many QRS complexes to 
reduce noise interference and thus may reveal subtle abnor-
malities) has been shown to be of additional benefit with a 
QRS duration <100 ms conferring up to 100% specificity in 
one study.35 Holter monitoring alone may be highly predic-
tive of CS abnormalities of supraventricular tachycardia, 
ventricular ectopic beats and AV block indicating cardiac 
involvement in sarcoidosis.36 Holter monitoring is a relatively 
inexpensive test that can be performed in the outpatient 
setting with patients being asked to return the monitor after 
the test period is complete.
There are no widely accepted blood- based markers for 
evaluation of cardiac disease in sarcoidosis. Levels of pro- 
BNP (pro- brain natriuretic peptide) has been investigated 
with one study of 150 patients showing association with CS 
with an area under the curve of 0.913.37 However, pro- BNP 
is not specific for CS and is elevated in a number of cardiac 
diseases.38 High sensitivity cardiac troponin T (hscTnT) has 
been investigated and shown to correlate with serum ACE 
levels and may be useful in diagnosing CS.39 hscTnT has also 
been shown in some patients to normalise with treatment 
of CS using corticosteroids.40 However, serum ACE alone is 
unhelpful in both diagnosis and monitoring of CS activity.
Proteins associated with CS could pave the way towards 
simple and cheap blood tests to assist with diagnosis but 
this technique has not yet been used in CS. In respect to 
proteomics in pulmonary sarcoidosis, Surface- enhanced laser 
desorption/ionization (SELDI) has been shown to identify 
serum proteins specific to radiographic stage of sarcoidosis,41 
and serum and bronchoalveolar cytokine profiles have been 
shown to differentiate between pulmonary forms of sarcoid-
osis and tuberculosis.42
CONCLUSIONS
The majority of patients with CS will initially present to 
respiratory teams and it is therefore important that the 
true prevalence of the condition is quantified, and that 
improved screening and diagnostic methods are developed. 
CS may present with a number of complications, including 
sudden death, in patients with pulmonary sarcoidosis who 
are unaware of having cardiac involvement. Additionally, 
patients with sarcoidosis are at higher risk of ischaemic heart 
disease, cardiac failure and pulmonary hypertension. The 
findings from the CASPA study will first identify the prev-
alence of CS in a population of patients with pulmonary 
sarcoidosis with no overt cardiac disease. Second, it will use 
ECG, signal- averaged ECG, speckle- tracking echocardio-
gram and 24- hour ambulatory Holter monitoring reports in 
all 104 study patients to look for combinations of these tests 
to be best used as a surrogate diagnosis for CS, using the MRI 
findings as the gold standard. Finally, a proteomic analysis will 
be performed on serum from all patients to look for serum 
biomarkers which may correlate with CS. We anticipate that 
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these results will add information to the literature of heart 
disease in sarcoidosis.
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